News

AstraZeneca to present scientific advancements from growing respiratory portfolio at ATS conference 2017

Amy Schofield 18 May 2017

AstraZeneca and its global biologics research and development arm, MedImmune, will present new data from its growing respiratory portfolio and pipeline at the 113th annual conference of the American Thoracic Society (ATS) this month in Washington, DC, USA.

The 59 accepted abstracts, including three oral presentations and 13 poster discussions, will focus on the unmet needs of asthma and chronic obstructive pulmonary disease (COPD). A highlight at ATS will be the reporting of data from two new trials from the WINDWARD programme for benralizumab, AstraZeneca’s most-advanced respiratory biologic medicine A highlight will be the reporting of data from two new trials from the WINDWARD programme for benralizumab, AstraZeneca’s most-advanced respiratory biologic medicine.

Tom Keith-Roach, Vice President, Respiratory at AstraZeneca, said: “We are particularly excited to share the results of the ZONDA trial, looking at the potential for benralizumab to reduce or discontinue oral corticosteroids, which are a significant burden to many patients with severe asthma.”

 

Make a comment

To voice your opinion, please Log in or Register.

Pf Magazine

Your resource for news, features, interviews, careers and events in the pharma industry.

Click here for the latest issue and to subscribe.